OpenNashEarnings

Boston Scientific (BSX) · Medical Devices

Boston Scientific Q2 2026 earnings: summary, key numbers & outlook

Results filed 29 Jul 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Boston Scientific bought into transcatheter aortic valves through a $1.5 billion MiRus stake while FARAPULSE and WATCHMAN faced share and referral pressure in the U.S.

Boston Scientific made a strategic move into transcatheter aortic valve replacement (TAVR) by investing $1.5 billion in MiRus for about 34% of the company and an exclusive option to buy its TAVR business. Clinical data advanced across the pipeline: FARAPULSE beat anti-arrhythmic drugs in persistent atrial fibrillation, and the SEISMIQ 4CE lithotripsy catheter met its primary endpoints. Growth was strongest in Neuromodulation, while Urology was nearly flat.

Management is steering toward new franchises, including TAVR, next-generation PFA catheters and coronary lithotripsy, and toward cost savings. The main tension is that the U.S. WATCHMAN market slowed sharply and PFA competitors are taking share faster than management expected. The company has lowered its outlook, and the new products must offset pressure in two core franchises.

No call transcript for this quarter, so this summary also draws on: Webull (Motley Fool transcript) ↗.

Key numbers

Net sales · GAAP
$5.442 billion

up 7.5% reported and 7.0% organic from a year ago

Net income attributable to common stockholders · GAAP
$907 million

vs. $797 million a year ago

Diluted EPS · GAAP
$0.61

vs. $0.53 a year ago

Adjusted EPS · non-GAAP
$0.86

vs. $0.75 a year ago

Operating income · GAAP
$1.2B

vs. $819 million a year ago

Segment or metricValueChange
MedSurg$1.8Bup 5.9% reported, 5.4% organic
Endoscopy$793.0Mup 7.6% reported, 7.0% organic
Urology$684.0Mup 1.1% reported, 0.8% organic
Neuromodulation$341.0Mup 12.7% reported, 12.2% organic
United States$3.4Bup 6.2% reported and operational
Asia-Pacific$878.0Mup 11.2% reported and operational
Latin America and Canada$206.0Mup 22.4% reported, 16.2% operational
Where each number comes from
  • Net sales: “Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis”
  • Net income attributable to common stockholders: “GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago”
  • Diluted EPS: “GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago”
  • Adjusted EPS: “achieved adjusted3 EPS of $0.86 for the period, compared to $0.75 a year ago”
  • Operating income: “Reported | $3,848 | $2,670 | $1,178 | $(118) | $1,060 | $905 | $(2) | $907 | $0.61”
  • MedSurg: “MedSurg | 1,818 | 1,716 | 5.9% | (0.5)% | 5.4% | —% | 5.4%”
  • Endoscopy: “Endoscopy | $793 | $737 | 7.6% | (0.7)% | 7.0% | —% | 7.0%”
  • Urology: “Urology | 684 | 676 | 1.1% | (0.3)% | 0.8% | —% | 0.8%”
  • Neuromodulation: “Neuromodulation | 341 | 303 | 12.7% | (0.6)% | 12.2% | —% | 12.2%”
  • United States: “U.S. | $3,426 | $3,224 | 6.2% | —% | 6.2% EMEA | 932 | 878 | 6.1% | (1.9)% | 4.2%”
  • Asia-Pacific: “APAC | 878 | 790 | 11.2% | (0.0)% | 11.2% LACA | 206 | 169 | 22.4% | (6.2)% | 16.2%”
  • Latin America and Canada: “APAC | 878 | 790 | 11.2% | (0.0)% | 11.2% LACA | 206 | 169 | 22.4% | (6.2)% | 16.2%”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$5.4B+7.5%+4.6%
Operating income$1.2B+43.8%+7.0%
Net income$905.0M+13.8%−32.4%
Diluted EPS$0.61+15.1%−32.2%
Free cash flow$1.3B+13.3%+648.0%
Gross margin70.7%+3.0 pts+1.2 pts
Operating margin21.6%+5.4 pts+0.4 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Net sales growth (reported and organic)third quarter of 20263 to 5 percent
Adjusted EPSthird quarter of 2026$0.80 to $0.82
Net sales growth (reported)full year 20265.5 to 6.5 percent
Net sales growth (organic)full year 20265 to 6 percent
Adjusted EPSfull year 2026$3.28 to $3.32

Key takeaways

  1. MiRus stake gives Boston Scientific a TAVR path

    Boston Scientific invested $1.5 billion in MiRus for about 34% equity and an exclusive option to acquire its TAVR business. The SIEGEL balloon-expandable valve is investigational and not available for sale.

  2. FARAPULSE showed superiority over drugs in persistent AF

    The AVANT GUARD study met all safety and effectiveness endpoints and showed statistical superiority over anti-arrhythmic drugs in previously untreated persistent AF. That supports using PFA earlier in the treatment path.

  3. Next-generation PFA catheter advances into a pivotal trial

    Early ELEVATE-PF data for the FARAFLEX map-and-ablate catheter showed strong lesion durability and no reported pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke. The pivotal FARADIGM trial has begun enrolling, as management faces PFA competition.

  4. U.S. PFA competition is taking share

    Management said it remains the PFA leader but its share has come down, and it had not anticipated the competitive share movement it is now seeing. U.S. PFA is now roughly 80% of the AFib market, so the pressure lands in a core franchise.

  5. WATCHMAN slowed as clinical evidence shifted referrals

    Management said the U.S. WATCHMAN market slowed sharply and unexpectedly, driven by compounding clinical evidence that changed referral patterns. It estimates about one-third of U.S. WATCHMAN procedures are now done together with another procedure.

Charts

Revenue$5.4B+7.5% y/yQ2 2026
Q4 2024: $4.6B (worked out from the annual figure)Q4 ’24$4.6BQ1 2025: $4.7BQ1 ’25$4.7BQ2 2025: $5.1BQ2 ’25$5.1BQ3 2025: $5.1BQ3 ’25$5.1BQ4 2025: $5.3B (worked out from the annual figure)Q4 ’25$5.3BQ1 2026: $5.2BQ1 ’26$5.2BQ2 2026: $5.4BQ2 ’26$5.4BQ3 2026: $5.1BQ3 ’26$5.1B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$4.6B *
Q1 2025$4.7B
Q2 2025$5.1B
Q3 2025$5.1B
Q4 2025$5.3B *
Q1 2026$5.2B
Q2 2026$5.4B
Q3 2026$5.1B
Diluted EPS (GAAP)$0.61+15.1% y/yQ2 2026
Q1 2025: $0.45Q1 ’25$0.45Q2 2025: $0.53Q2 ’25$0.53Q3 2025: $0.51Q3 ’25$0.51Q1 2026: $0.90Q1 ’26$0.90Q2 2026: $0.61Q2 ’26$0.61Q3 2026: $0.40Q3 ’26$0.40
Data
Q1 2025$0.45
Q2 2025$0.53
Q3 2025$0.51
Q1 2026$0.90
Q2 2026$0.61
Q3 2026$0.40

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin21.6%+5.4 pts y/yQ2 2026
Q4 2024: 14.8%Q4 ’2414.8%Q1 2025: 19.8%Q1 ’2519.8%Q2 2025: 16.2%Q2 ’2516.2%Q3 2025: 20.7%Q3 ’2520.7%Q4 2025: 15.6%Q4 ’2515.6%Q1 2026: 21.2%Q1 ’2621.2%Q2 2026: 21.6%Q2 ’2621.6%Q3 2026: 16.1%Q3 ’2616.1%
Data
Q4 202414.8%
Q1 202519.8%
Q2 202516.2%
Q3 202520.7%
Q4 202515.6%
Q1 202621.2%
Q2 202621.6%
Q3 202616.1%
Free cash flow$1.3B+13.3% y/yQ2 2026
Q4 2024: $1.2BQ4 ’24$1.2BQ1 2025: $354.0MQ1 ’25$354.0MQ2 2025: $1.1BQ2 ’25$1.1BQ3 2025: $1.2BQ3 ’25$1.2BQ4 2025: $1.0BQ4 ’25$1.0BQ1 2026: $171.0MQ1 ’26$171.0MQ2 2026: $1.3BQ2 ’26$1.3BQ3 2026: $868.0MQ3 ’26$868.0M
Data
Q4 2024$1.2B
Q1 2025$354.0M
Q2 2025$1.1B
Q3 2025$1.2B
Q4 2025$1.0B
Q1 2026$171.0M
Q2 2026$1.3B
Q3 2026$868.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is Boston Scientific's MiRus deal?

Boston Scientific invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire the MiRus TAVR business. MiRus's SIEGEL balloon-expandable TAVR system is investigational.

What clinical data did Boston Scientific report for FARAPULSE and its next PFA catheter?

AVANT GUARD showed FARAPULSE was statistically superior to anti-arrhythmic drugs in previously untreated persistent AF. The FARAFLEX catheter showed strong lesion durability in ELEVATE-PF, and its pivotal FARADIGM trial has started enrolling.

What is happening with WATCHMAN in the U.S.?

Management said the U.S. market slowed sharply and unexpectedly, driven by clinical evidence that changed referral patterns. About one-third of U.S. WATCHMAN procedures are now done concomitantly.

How is competition affecting Boston Scientific's PFA business?

Management said it remains the PFA leader but its U.S. share has come down, and it did not anticipate the degree of competitive share movement. U.S. PFA now makes up roughly 80% of the AFib market.

What new products are coming to market?

The SEISMIQ 4CE coronary lithotripsy catheter met its primary endpoints in the FRACTURE trial, and management expects to bring it to market in the first half of 2027. The company also received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter.

Documents

SEC filing